---
title: "4503.JP (4503.JP) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/4503.JP/news.md"
symbol: "4503.JP"
name: "4503.JP"
parent: "https://longbridge.com/en/quote/4503.JP.md"
datetime: "2026-05-20T12:59:47.912Z"
locales:
  - [en](https://longbridge.com/en/quote/4503.JP/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/4503.JP/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/4503.JP/news.md)
---

# 4503.JP (4503.JP) — Related News

### [Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News](https://longbridge.com/en/news/286767626.md)
*2026-05-18T04:00:00.000Z*
> Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and

### [SMC backs first-line metastatic bladder cancer combination after trial results](https://longbridge.com/en/news/286065296.md)
*2026-05-12T08:59:43.000Z*
> The Scottish Medicines Consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults 

### [NEJM: The new drug setidegrasib directly degrades the KRAS G12D protein, bringing early hope for lung cancer and pancreatic cancer](https://longbridge.com/en/news/285786940.md)
*2026-05-09T01:00:29.000Z*
> The NEJM reported that the novel drug setidegrasib shows early activity in lung cancer and pancreatic cancer patients wi

### [Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?](https://longbridge.com/en/news/284702726.md)
*2026-04-30T05:55:32.000Z*
> Astellas Pharma Inc. (TSE:4503) reported yearly earnings, with shares dropping 7.8% to JP¥2,306. Revenues met forecasts 

### [Astellas Pharma (TSE:4503) Margin Surge To 13.6% Tests Bearish Earnings Narratives](https://longbridge.com/en/news/284357343.md)
*2026-04-28T10:02:01.000Z*
> Astellas Pharma (TSE:4503) reported a FY 2026 scorecard with second half revenue of ¥1.1t and basic EPS of ¥80.33, refle

### [Astellas Pharma (ALPMF) Receives a Hold from UBS](https://longbridge.com/en/news/282988331.md)
*2026-04-16T10:59:04.000Z*
> UBS analyst maintained a Hold rating on Astellas Pharma today and set a price target of Yen2,600.00.Claim 30% Off TipRan

### [How Investors Are Reacting To Astellas Pharma (TSE:4503) XOSPATA Frontline AML Trial Missing Survival Goal](https://longbridge.com/en/news/279521085.md)
*2026-03-18T02:27:00.000Z*
> Astellas Pharma's Phase 3 trial of XOSPATA for acute myeloid leukemia missed its primary survival goal, showing similar